Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
|
|
- Virginia Henderson
- 5 years ago
- Views:
Transcription
1 Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis JULIE A. BJORAKER, JAY H. RYU, MARK K. EDWIN, JEFFREY L. MYERS, HENRY D. TAZELAAR, DARRELL R. SCHROEDER, and KENNETH P. OFFORD Division of Pulmonary and Critical Care Medicine, Mayo Graduate School of Medicine, Division of Anatomic Pathology, and the Section of Biostatistics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota Idiopathic pulmonary fibrosis (IPF) is a generally fatal disorder with a reported median survival of 3 to 6 yr. This has been based on relatively few studies with diagnoses inconsistently confirmed by adequate lung biopsy. Retrospective analysis of 104 patients with IPF who had open lung biopsy (OLB) at Mayo Medical Center from 1976 to 1985 was performed to establish the overall survival rate, the spectrum of histopathological subgroups and their associated prognostic significance. The study group consisted of 54 men and 50 women with a median age of 63 yr. Median survival was 3.8 yr after diagnosis by OLB with an estimated 10 yr survival of 27%. Current histopathologic review showed a heterogeneous group including usual interstitial pneumonia (UIP), desquamative interstitial pneumonia (DIP), nonspecific interstitial pneumonia/fibrosis (NSIP), acute interstitial pneumonia (AIP), bronchiolitis, bronchiolitis obliterans organizing pneumonia (BOOP), and others. Median survival of the UIP group was 2.8 yr which is significantly worse (p 0.001) than for other subgroups of chronic interstitial pneumonias. IPF includes several histopathologic subgroups with significantly different survival rates. Patients with UIP have worse survival than patients with other types of idiopathic chronic interstitial pneumonias including NSIP. Accurate histopathologic classification is essential for prognostication in patients with IPF. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. AM J RESPIR CRIT CARE MED 1998;157: (Received in original form April 29, 1997 and in revised form August 8, 1997) Correspondence and requests for reprints should be addressed to Dr. Jay H. Ryu, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, MN Am J Respir Crit Care Med Vol 157. pp , 1998 Idiopathic pulmonary fibrosis (IPF), also called cryptogenic fibrosing alveolitis, is a clinicopathologic term referring to a generally fatal disorder of unknown cause characterized by varying degrees of inflammation and fibrosis in the lung parenchyma (1 5). Mean survival in IPF has been estimated to be 3 to 6 yr but with a variable clinical course (2, 6 10). This estimate has been based on relatively few studies with diagnoses inconsistently established by adequate, i.e., open or thoracoscopic, lung biopsy (2, 6, 8, 9). Pathologic review of lung specimens from IPF patients may show a variety of histologic patterns (6 8, 10, 11). Usual interstitial pneumonia (UIP) is a specific histologic pattern of fibrosing interstitial pneumonia seen in the majority of patients with IPF. In this sense, UIP and IPF are considered synonyms. Over the past 15 yr, several lung injury patterns have been delineated as potential mimics of IPF. Bronchiolitis obliterans organizing pneumonia (BOOP) (12), acute interstitial pneumonia (AIP) (13), and respiratory bronchiolitis associated interstitial lung disease (RB/ILD) (14) have been separated as unique clinicopathologic subgroups with a distinctly different natural history than IPF. Recently, Katzenstein and Fiorelli (15) described a pattern of chronic interstitial pneumonia referred to as nonspecific interstitial pneumonia/fibrosis (NSIP) in patients with a variety of clinical syndromes and with histology distinct from UIP. With the exception of AIP, these other entities are associated with a greater likelihood of responding to corticosteroid therapy and better prognosis than UIP. We reviewed our experience over a 10-yr period to further investigate the significance of histopathologic findings in patients with IPF. METHODS Patient Selection Surgical and medical index information on 152 patients previously diagnosed with IPF was linked to that of 479 patients who underwent open lung biopsy (OLB) at Mayo Medical Center over a 10-yr period. The years were chosen to allow for adequate follow-up. Medical records were reviewed and patients with evidence of connective tissue disease or environmental exposures known to cause interstitial lung disease were excluded. There were 104 patients with IPF who met the study criteria. These patients manifested clinical, physiologic, and radiographic features of IPF as previously described (1, 2). Data Collection The medical records were reviewed for information related to the patient s age, sex, smoking history, occupation, symptoms, signs, environmental exposures, associated disorders, medications, laboratory tests, pulmonary function tests, arterial blood gas studies, treatment, and outcome. The date of OLB at the Mayo Medical Center was used as the date of diagnosis. A mailed survey was used to obtain vital sta-
2 200 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL tus information for all not known to be deceased as of April 15, Date of death was obtained from death certificates or next of kin. Pathologic Review All 104 patients had previously undergone OLB and had the diagnosis of IPF made based on the biopsy results. Pathologic material was available for current rereview from 102 of the 104 patients (98%) and was reviewed by two of us (H.D.T., J.L.M.) in a blinded fashion and classified into five histopathologic categories: UIP, desquamative interstitial pneumonia (DIP), NSIP, AIP, and others. Usual interstitial pneumonia (7) is characterized by a heterogeneous appearance at low magnification with alternating zones of normal lung, collagen fibrosis, and honeycomb change. Scattered foci of fibroblast proliferation are also usually present. The fibrotic changes preferentially affect subpleural and paraseptal parenchyma. Patchy chronic inflammation accompanies the interstitial fibrosis, and consists mainly of lymphocytes, plasma cells, and histiocytes with a minor component of neutrophils and eosinophils. Desquamative interstitial pneumonia (7) is less variegated than UIP. Alveolar septa are thickened in a more uniform fashion, by a combination of connective tissue and an inflammatory infiltrate that often includes plasma cells and occasional eosinophils. The most striking feature is the presence of numerous pigmented macrophages within affected airspaces. Nonspecific interstitial pneumonia/ fibrosis (15) represents a pattern of chronic interstitial pneumonia that lacks characteristic features of other specific entities such as UIP, DIP, hypersensitivity pneumonitis, BOOP, Langerhans cell granulomatosis, or chronic eosinophilic pneumonia. Lung biopsies in this group are characterized by varying proportions of chronic interstitial inflammation and fibrosis which is temporally uniform (i.e., the process appears to have occurred over a single time span). This is in sharp contrast to the temporally heterogeneous pattern of UIP, related in part to an admixture of recent organization ( fibroblast foci ) and old collagen-rich scars. In the past such cases have been reported as cellular interstitial pneumonia, not otherwise specified (16, 17). Acute interstitial pneumonia (13), also referred to as Hamman-Rich syndrome, is characterized histologically by changes typical of acute and organizing diffuse alveolar damage. Remaining cases included several unrelated entities such as chronic eosinophilic pneumonia, hypersensitivity pneumonitis, nonspecific chronic bronchiolitis, RB/ILD, and BOOP. Statistical Analysis Cumulative survival probabilities were estimated using the Kaplan- Meier method (18) and compared with the general life expectancy for the white population of the West North Central region of the United States (19) for persons of like age, sex, and calendar year of birth using a one-sample log-rank test (20). The log-rank test (21) was used to compare survival of groups of patients. Three-year expected survival probability was determined for each patient (based on age, sex, and calendar year of birth using West North Central population survival tables), and a Cox proportional hazards regression model was used to compare survival between histopathologic subgroups after adjusting for 3-yr expected survival probability. In all cases two-sided tests were used with p values 0.05 used as evidence of findings not attributable to chance. RESULTS Table 1 shows the characteristics of the entire IPF group at the time of diagnosis. There were 54 men and 50 women with a median age of 63 yr. Forty-two percent had never smoked. Most patients had experienced exertional dyspnea (90%) and cough (81%) with a median duration of 6 and 5 mo, respectively, prior to OLB. Twenty-two percent had been treated with corticosteroids prior to lung biopsy. On exam, 80% had inspiratory crackles and 25% displayed digital clubbing. Parenchymal changes on chest radiograph were present in 98%. Most patients had a restrictive pattern on pulmonary function testing and exercise-induced desaturation. Following OLB, 89% were treated with prednisone. TABLE 1 CLINICAL FINDINGS AT THE TIME OF DIAGNOSIS IN 104 PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS Characteristic* % n Median Mean SD Range Sex Male Female Age, yr Smoking status Current Former Never Symptoms Exertional dyspnea (n 97) Duration, mo Cough (n 97) Duration, mo Signs Crackles Clubbing (n 100) Radiographic infiltrates (n 103) Pulmonary function (n 84) Normal 2 2 Obstructed Restricted Mixed 6 5 Nonspecific 6 5 Oxygen saturation, % Rest (n 88) Exercise (n 55) Corticosteroid treatment At the time of diagnosis Immediately following diagnosis * Number of patients with information available is 104, except where indicated. The histopathologic diagnoses and number of cases in each following rereview of the OLB slides are shown in Table 2. Only 62% of the cases were found to have UIP. The next most common diagnosis was NSIP. For the purpose of analyzing the prognostic significance, the cases were divided into three main subgroups: UIP, NSIP, and Others. The Others subgroup consisted of several chronic interstitial lung diseases (DIP, bronchiolitis, BOOP, RB/ILD, chronic eosinophilic pneumonia, hypersensitivity pneumonia) that have historically been associated with a higher response rate to corticosteroid therapy and a TABLE 2 HISTOPATHOLOGIC DIAGNOSES IN 102 PATIENTS* WITH IDIOPATHIC PULMONARY FIBROSIS Histopathological Diagnosis % n Usual interstitial pneumonia Nonspecific interstitial pneumonia/fibrosis Desquamative interstitial pneumonia 8 8 Bronchiolitis 4 4 Bronchiolitis obliterans organizing pneumonia 4 4 Respiratory bronchiolitis associated interstitial lung disease 2 2 Chronic eosinophilic pneumonia 1 1 Hypersensitivity pneumonitis 1 1 Acute interstitial pneumonia 2 2 Honeycomb change only 1 1 Hemorrhage 1 1 Scarring and pneumonia 1 1 * A total of 104 patients were diagnosed with IPF via open lung biopsy at the Mayo Medical Center during the 10-yr period from 1976 through Pathologic material was available for current histopathologic review from 102 of these patients.
3 Bjoraker, Rhu, Edwin, et al.: Prognosis in Pulmonary Fibrosis 201 TABLE 3 CLINICAL CHARACTERISTICS ACCORDING TO HISTOPATHOLOGIC SUBGROUP Characteristic UIP (n 63)* NSIP Others (n 14) (n 20) p Value Sex, % Male Female Age, yr Mean SD Range Smoking status, % Current Former Never Symptoms Exertional dyspnea, % NS Duration, mo (mean SD) NS Cough, % NS Duration, mo (mean SD) NS Signs Crackles, % Clubbing, % NS Radiographic infiltrates, % NS Oxygen saturation, % Rest (mean SD) NS Exercise (mean SD) NS Corticosteroid treatment, % At the time of diagnosis NS Immediately following diagnosis NS * Usual interstitial pneumonia. n 63 for all characteristics except: exertional dyspnea (n 57); cough (n 60); clubbing (n 62); radiographic infiltrates (n 62); oxygen saturation at rest (n 52); and oxygen saturation with exercise (n 35). Nonspecific interstitial pneumonia/fibrosis. n 14 for all characteristics except: cough (n 13); oxygen saturation at rest (n 11); and oxygen saturation with exercise (n 7). Includes desquamative interstitial pneumonia (n 8), bronchiolitis (n 4), bronchiolitis obliterans organizing pneumonia (n 4), respiratory bronchiolitis associated interstitial lung disease (n 2), chronic eosinophilic pneumonia (n 1), and hypersensitivity pneumonitis (n 1). Overall n 20 for all characteristics except: exertional dyspnea (n 19); cough (n 17); clubbing (n 18); oxygen saturation at rest (n 18); and oxygen saturation with exercise (n 12). p Value associated with the overall comparison across histopathologic subgroups using analysis of variance for continuous variables and exact test for categorical variables. NS not significant (p 0.05). better prognosis than UIP. Two patients with AIP, three patients with nondiagnostic histopathologic findings (honeycomb change only, hemorrhage, scarring and pneumonia, respectively), and two patients whose biopsy slides were unobtainable for current histopathologic review were excluded from this analysis. Table 3 describes the clinical characteristics of the three main histopathological subgroups, UIP, NSIP, and Others at Characteristic TABLE 4 PULMONARY FUNCTION ACCORDING TO HISTOPATHOLOGIC SUBGROUP UIP NSIP Others* n Mean SD n Mean SD n Mean SD p Value TLC, % pred FVC, % pred NS FEV 1, % pred NS DL CO, % pred NS Definition of abbreviations: UIP usual interstitial pneumonia; NSIP nonspecific interstitial pneumonia/fibrosis; DL CO diffusing capacity of the lungs for carbon monoxide. * Includes desquamative interstitial pneumonia (n 8), bronchiolitis (n 4), bronchiolitis obliterans organizing pneumonia (n 4), respiratory bronchiolitis associated interstitial lung disease (n 2), chronic eosinophilic pneumonia (n 1), and hypersensitivity pneumonitis (n 1). Number of patients with information available for the given characteristic. p Value associated with the overall comparison across histopathologic subgroups using analysis of vaiance. NS not significant (p 0.05). the time of the OLB-based diagnosis of IPF. Patients with UIP were older with a mean of 65 yr compared with 57 yr and 54 yr in the NSIP and Others subgroups, respectively. Current smoking was more frequent in the Others group likely due to cases of bronchiolitis, RB/ILD, and DIP (14). Table 4 outlines the pulmonary function data obtained for the three subgroups. UIP patients had a significantly lower total lung capacity (% predicted normal) compared with the Others category. There were no other significant differences in other physiologic parameters including arterial blood gas results (data not shown). Seventy-six of the 104 patients are known to be deceased. Recent follow-up was obtained for 23 of the 28 remaining patients, all with more than 8.5 yr of follow-up. Five patients were lost to follow-up at 11 d, 7, 8, 23, and 32 mo. Observed versus expected survival for the IPF patients is shown in Figure 1. There is a significant (p 0.001) decrease in survival for IPF patients. Comparison of survival in the three main histopathologic subgroups is shown in Figure 2. UIP has significantly worse survival compared with NSIP and Others (p 0.001). In a multivariate survival analysis, UIP was still found to have significantly (p 0.001) worse survival than NSIP and Others, after adjusting for 3-yr expected survival probability. Two patients with AIP both died within 1 mo of their diagnosis as did the patient with diffuse pulmonary hemorrhage and the patient with honeycomb change. The patient with nonspecific scarring and bronchopneumonia survived 2.8 yr. One patient for whom pathologic material was unavailable for rereview survived 3.3 yr, and the other was still alive after 8.8 yr.
4 202 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL Figure 1. Overall survival of 104 patients diagnosed with idiopathic pulmonary fibrosis (IPF) via open lung biopsy: observed versus expected rate. For the entire group of patients with IPF, survival was significantly worse (p 0.001) than the expected rate based on all cause mortality for persons in the general population of the West North Central region of the U.S. of like age, sex, and calendar year of birth. p Value is from the one-sample log rank test comparison of the observed and expected survival curves. DISCUSSION Our findings demonstrate the heterogeneity of histopathologic findings in patients with the clinical syndrome of IPF. The survival rate for our group as a whole is very similar to that reported in previous studies (2, 6, 8 10). Our patients also had similar clinical findings in that they were middle-aged or older, presented with exertional dyspnea and chronic cough, and had diffuse bilateral radiographic infiltrates. Histologically confirmed UIP was associated with a significantly worse prognosis than other histologic patterns of chronic interstitial pneumonia including NSIP. Our findings are consistent with the results of the study by Katzenstein and Fiorelli (15) who demonstrated a better prognosis for patients with NSIP than that associated with UIP. Although our UIP patients were older, survival differences remained significant even after adjusting for 3-yr expected survival based on age, sex, and calendar year of birth. Liebow and Carrington (22) recognized 30 yr ago that patients with IPF were a heterogeneous group and emphasized the value of separating histologic patterns to predict natural history. Several frequently quoted studies analyzing survival in patients with IPF have been hampered by potentially inadequate pathologic analysis (2, 6, 8 10). For example, Turner- Warwick and colleagues (2) reported on 220 patients with IPF in whom biopsy material was available for review in only 42 cases, including trephine and other needle biopsies. Autopsy specimens were examined in 26 cases. Histopathologic confirmation of UIP is now known to be difficult in small lung biopsy specimens including those obtained by bronchoscopy and needle methods (23). Our study included only patients who had open lung biopsy and a minimum potential for 8 yr of follow-up. Classification of interstitial pneumonias has evolved in recent years. Although Hamman and Rich (24) are sometimes credited with the initial description of IPF, their patients contrast sharply with classic descriptions of IPF in that they pursued a fulminant and rapidly fatal course. AIP is a more recently proposed synonym for Hamman-Rich syndrome to underscore clinical and morphologic differences from IPF (13, 25). Indeed, our two patients with AIP died within 1 mo of diagnosis. In 1978, Carrington and colleagues delineated the differences between UIP and DIP and reported a higher response rate to corticosteroid therapy and a significantly better survival rate in patients with DIP (7). Since then, other interstitial lung disorders or histologic patterns have been described which also need to be distinguished from UIP. These include BOOP, RB-ILD, and most recently, NSIP (12 15). These entities may resemble IPF clinically, physiologically, and radiographically, but are associated with a higher response rate to corticosteroid therapy and a better prognosis. These observations raise questions about the extent to which historical observations of a 15 to 30% objective response rate to corticosteroid therapy reported in patients with IPF apply to patients with carefully defined UIP (2, 6, 8 10). We suspect that responders to corticosteroid therapy reported in previous studies may include patients with interstitial lung diseases other than UIP. Given the complications associated with long-term corticosteroid therapy, there is a need to clarify the role of corticosteroid therapy in patients with UIP. Our data suggest that DIP and NSIP represent separate and distinct entities rather than earlier forms of UIP (5, 7, 11). This conclusion is supported not only by differences in radiographic and histologic findings but also significant differences in survival curves that cannot be explained by differences in age at diagnosis (26 28). Our study reiterates that patients with IPF demonstrate heterogeneous lesions. Histopathological subtypes represent a dominant prognostic factor in patients with IPF. Histologically confirmed UIP is associated with a substantially worse survival than other categories of chronic interstitial pneumonia. These findings have important implications for advising IPF patients about the usefulness of corticosteroid therapy, prognosis, and timing of lung transplantation. Figure 2. Observed survival according to histopathological subgroups. Patients with UIP had a significantly worse survival (p 0.001, rank sum test) compared with nonspecific interstitial pneumonia/fibrosis and Others subgroups. Median survival for UIP patients was 2.8 yr. References 1. Crystal, R. G., J. D. Fulmer, W. C. Roberts, M. L. Moss, B. R. Line, and H. Y. Reynolds Idiopathic pulmonary fibrosis: clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann. Intern. Med. 85: Turner-Warwick, M., B. Burrows, and A. Johnson Cryptogenic fi-
5 Bjoraker, Rhu, Edwin, et al.: Prognosis in Pulmonary Fibrosis 203 brosing alveolitis: clinical features and their influence on survival. Thorax 35: Raghu, G Idiopathic pulmonary fibrosis: a rational clinical approach. Chest 92: Cherniak, R. M., R. G. Crystal, and A. R. Kalica Current concepts in idiopathic pulmonary fibrosis: a road map for the future. Am. Rev. Respir. Dis. 143: King, T. E., Jr Idiopathic pulmonary fibrosis. In M. I. Schwarz and T. E. King, Jr., editors. Interstitial Lung Disease, 2nd ed. Mosby Year Book, St. Louis Stack, B. H. R., Y. F. J. Choo-Kang, and B. E. Heard The prognosis of cryptogenic fibrosing alveolitis. Thorax 27: Carrington, C. B., E. A. Gaensler, R. E. Coutu, M. X. FitzGerald, and R. G. Gupta Natural history and treated course of usual and desquamative interstitial pneumonia. N. Engl. J. Med. 298: Turner-Warwick, M., B. Burrows, and A. Johnson Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 35: Tukiainen, P., E. Taskinen, P. Holsti, O. Kohola, and M. Valle Prognosis of cryptogenic fibrosing alveolitis. Thorax 38: Wright, P. H., B. E. Heard, S. J. Steel, and M. Turner-Warwick Cryptogenic fibrosing alveolitis: assessment by graded trephine lung biopsy compared with clinical, radiographic, and physiologic features. Br. J. Dis. Chest 75: Meier-Sydow, J., S. M. Weiss, R. Buhl, M. Rust, and G. Raghu Idiopathic pulmonary fibrosis: current clinical concepts and challenges in management. Sem. Respir. Crit. Care Med. 15: Epler, G. R., T. V. Colby, T. C. McCloud, C. B. Carrington, and E. A. Gaensler Bronchiolitis obliterans organizing pneumonia. N. Engl. J. Med. 312: Katzenstein, A. A., J. L. Myers, and M. Mazur Acute interstitial pneumonia: a clinicopathologic, ultrastructural, and cell kinetic study. Am. J. Surg. Pathol. 10: Myers, J. L., C. F. Veal, Jr., M. S. Shin, and A. A. Katzenstein Respiratory bronchiolitis causing interstitial lung disease: a clinicopathologic study of six cases. Am. Rev. Respir. Dis. 135: Katzenstein, A. A., and R. F. Fiorelli Nonspecific interstitial pneumonia/fibrosis: histologic features and clinical significance. Am. J. Surg. Pathol. 18: Tazelaar, H. D., R. W. Viggiano, J. Pickersgill, and T. V. Colby Interstitial lung disease in polymyositis and dermatomyositis: clinical features and prognosis as correlated with histologic findings. Am. Rev. Respir. Dis. 141: Yousem, S. A., T. V. Colby, and C. B. Carrington Lung biopsy in rheumatoid arthritis. Am. Rev. Respir. Dis. 131: Kaplan, E. L., and P. Meier Non-parametric estimation from incomplete observations. J.A.S.A. 53: Berstralh, E. J., and K. P. Offord. Conditional Probabilities Used in Calculating Cohort Expected Survival. Section of Biostatistics, Mayo Clinic. Technical Report Series No. 37, January Fleming, T. R., and D. P. Harrington A class of hypothesis tests for one and two sample censored survival data. Commun. Stat. A10 (8): Mantel, N Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50: Liebow, A. A., and C. B. Carrington Alveolar diseases. The interstitial pneumonias. In M. Simon, editor. Frontiers of Pulmonary Radiology. Grune and Stratton, New York. 23. Wall, C. P., E. A. Gaensler, C. B. Carrington, and J. A. Hayes Comparison of transbronchial and open biopsies in chronic infiltrative lung diseases. Am. Rev. Respir. Dis. 123: Hamman, L., and A. R. Rich Acute diffuse interstitial fibrosis of the lungs. Bull. Johns Hopkins Hosp. 74: Olson, J., T. V. Colby, and C. G. Elliott Hamman-Rich syndrome revisited. Mayo Clin. Proc. 65: Park, J. S., K. S. Lee, J. S. Kim, C. S. Park, Y.-L. Suh, and D. L. Choi, and K. J. Kim Nonspecific interstitial pneumonia with fibrosis: radiographic and CT findings in seven patients. Radiology 195: Hartman, T. E., S. L. Primack, E.-Y. Kang, S. J. Swensen, D. M. Hansell, and G. McGuiness, and N. L. Müller Disease progression in usual interstitial pneumonia compared with desquamative interstitial pneumonia: assessment with serial CT. Chest 110: Akira, M., S. Yamamoto, H. Hara, M. Sakatani, and E. Ueda Serial computed tomographic evaluation in desquamative interstitial pneumonia. Thorax 52:
Diffuse interstitial lung diseases (DILDs) are a heterogeneous group of non-neoplastic, noninfectious
Focused Issue of This Month Diagnostic Approaches to Diffuse Interstitial Lung Diseases Dong Soon Kim, MD Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine E -
More information4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs
Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation
More informationZOE D. DANIIL, FRANCES C. GILCHRIST, ANDREW G. NICHOLSON, DAVID M. HANSELL, JESSICA HARRIS, THOMAS V. COLBY, and ROLAND M. du BOIS
A Histologic Pattern of Nonspecific Interstitial Pneumonia Is Associated with a Better Prognosis Than Usual Interstitial Pneumonia in Patients with Cryptogenic Fibrosing Alveolitis ZOE D. DANIIL, FRANCES
More informationInternational consensus statement on idiopathic pulmonary fibrosis
Eur Respir J 2001; 17: 163 167 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 PERSPECTIVE International consensus statement on idiopathic
More informationLiebow and Carrington's original classification of IIP
Liebow and Carrington's original classification of IIP-- 1969 Eric J. Stern MD University of Washington UIP Usual interstitial pneumonia DIP Desquamative interstitial pneumonia BIP Bronchiolitis obliterans
More informationANDREW G. NICHOLSON, THOMAS V. COLBY, ROLAND M. DUBOIS, DAVID M. HANSELL, and ATHOL U. WELLS
The Prognostic Significance of the Histologic Pattern of Interstitial Pneumonia in Patients Presenting with the Clinical Entity of Cryptogenic Fibrosing Alveolitis ANDREW G. NICHOLSON, THOMAS V. COLBY,
More informationPrognosis of cryptogenic fibrosing alveolitis
P TUKIAINEN, E TASKINEN, P HOLSTI, 0 KORHOLA, AND M VALLE Thorax 1983;38:349-355 From the Departments of Pulmonary Diseases, Oncology, and Diagnostic Radiology, University Central Hospital ofhelsinki,
More informationCareful histopathological evaluation has shown the traditionally clinical diagnosis of
Demystifying Idiopathic Interstitial Pneumonia Harold R. Collard, MD; Talmadge E. King, Jr, MD REVIEW ARTICLE Careful histopathological evaluation has shown the traditionally clinical diagnosis of idiopathic
More informationNONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP
UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF () FOR PATHOLOGISTS Thomas V. Colby, M.D. Professor of Pathology (Emeritus) Mayo Clinic Arizona FINANCIAL DISCLOSURES NONE OVERVIEW IPF Radiologic Dx Pathologic
More informationKey words: CT scanners; interstitial lung diseases; polymyositis-dermatomyositis; x-ray
Nonspecific Interstitial Pneumonia Associated With Polymyositis and Dermatomyositis* Serial High-Resolution CT Findings and Functional Correlation Hiroaki Arakawa, MD; Hidehiro Yamada, MD; Yasuyuki Kurihara,
More informationUnpaid scientific collaborator & advisor with Veracyte, Inc.
Diagnosis and Classification of Idiopathic Interstitial Pneumonias: Role of Histopathology in the Golden Age of Consensus Jeffrey L. Myers, M.D. A. James French Professor of Diagnostic Pathology Vice Chair
More information5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective No, I am not a pulmonologist! Radiology Pathology Clinical 1 Everyone needs a CT Confidence in diagnosis Definitive HRCT +
More informationCase Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco
Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary
More informationCTD-related Lung Disease
13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of
More informationTerminal Diffuse Alveolar Damage in Relation to Interstitial Pneumonias An Autopsy Study
Anatomic Pathology / DIFFUSE ALVEOLAR DAMAGE AS A TERMINAL EVENT Terminal Diffuse Alveolar Damage in Relation to Interstitial Pneumonias An Autopsy Study Alexandra J. Rice, MBBChir, 1 Athol U. Wells, MD,
More informationCase 4 History. 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar
Case 4 History 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar basilar infiltrates suggestive of pulmonary fibrosis Open
More informationSurvival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia
Eur Respir J 2002; 19: 1114 1118 DOI: 10.1183/09031936.02.00244002 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Survival of patients with
More informationNon-neoplastic Lung Disease II
Pathobasic Non-neoplastic Lung Disease II Spasenija Savic Prince Pathology Program Systematic approach to surgical lung biopsies with ILD Examples (chronic ILD): Idiopathic interstitial pneumonias: UIP,
More information11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective Radiology Pathology Clinical 1 Role of HRCT Diagnosis Fibrosis vs. inflammation Next step in management Response to treatment
More informationBronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy
Idiopathic Pulmonary Fibrosis Bronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy JMAJ 46(11): 469 474, 2003 Yukihiko SUGIYAMA Professor, Division of Pulmonary Medicine, Department of
More informationUsual Interstitial pneumonia and Nonspecific Interstitial Pneumonia. Nitra and the Gangs.
Usual Interstitial pneumonia and Nonspecific Interstitial Pneumonia Nitra and the Gangs. บทน ำและบทท ๓, ๑๐, ๑๒, ๑๓, ๑๔, ๑๕, ๑๗ Usual Interstitial Pneumonia (UIP) Most common & basic pathologic pattern
More informationColchicine versus Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis A Randomized Prospective Study
Colchicine versus Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis A Randomized Prospective Study WILLIAM W. DOUGLAS, JAY H. RYU, STEPHEN J. SWENSEN, KENNETH P. OFFORD, DARRELL R. SCHROEDER,
More informationFinancial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature
Financial disclosure I have no financial relationships to disclose. Douglas Johnson D.O. Cardiothoracic Imaging Gaston Radiology COMMON DIAGNOSES IN HRCT High Res Chest Anatomy Nomenclature HRCT Sampling
More informationOutline Definition of Terms: Lexicon. Traction Bronchiectasis
HRCT OF IDIOPATHIC INTERSTITIAL PNEUMONIAS Disclosures Genentech, Inc. Speakers Bureau Tadashi Allen, MD University of Minnesota Assistant Professor Diagnostic Radiology 10/29/2016 Outline Definition of
More informationINTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018
INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial
More informationDifferential diagnosis
Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential
More informationDIAGNOSTIC NOTE TEMPLATE
DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the
More informationDiagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines
Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines Rebecca Keith, MD Assistant Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO Objectives
More informationSurvival in Patients With Cryptogenic Fibrosing Alveolitis*
Survival in Patients With Cryptogenic Fibrosing Alveolitis* A Population-Based Cohort Study Richard Hubbard, DM; Ian johnston, MD; and john Britton, MD Study objectives: To determine the median survival
More informationDiffuse Interstitial Lung Diseases: Is There Really Anything New?
: Is There Really Anything New? Sujal R. Desai, MBBS, MD ESTI SPEAKER SUNDAY Society of Thoracic Radiology San Antonio, Texas March 2014 Diffuse Interstitial Lung Disease The State of Play DILDs Is There
More informationA Rapidly Progressive Case of Interstitial Pneumonia
CASE REPORT A Rapidly Progressive Case of Interstitial Pneumonia Toshiyuki Katoh, Takashi Ohishi, Nobuya Ikuta, Yoshinori Kawabata*, Kenzo Takagi and Tetsuo Hayakawa Wetreated a 51-year-old womanwho had
More informationSmoking-related lung pathology represents a histologically
A Review of Smoking-Related Interstitial Fibrosis, Respiratory Bronchiolitis, and Desquamative Interstitial Pneumonia Overlapping Histology and Confusing Terminology Smoking-related lung diseases traverse
More informationReplacement of air with fluid, inflammatory. cells or cellular debris. Parenchymal, Interstitial (Restrictive) and Vascular Diseases.
Parenchymal, Interstitial (Restrictive) and Vascular Diseases Alain C. Borczuk, M.D. Dept of Pathology Replacement of air with fluid, inflammatory cells Pulmonary Edema Pneumonia Hemorrhage Diffuse alveolar
More informationNonspecific interstitial pneumonia and usual interstitial pneumonia: comparison of the clinicopathologic features and prognosis
Original Article Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparison of the clinicopathologic features and prognosis Xia Li 1, Chang Chen 2, Jinfu Xu 1, Jinming Liu 1, Xianghua
More informationIdiopathic Pulmonary Fibrosis: The Importance of Qualitative and Quantitative Phenotyping
Idiopathic Pulmonary Fibrosis: The Importance of Qualitative and Quantitative Phenotyping K. R. Flaherty Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor,
More informationA Review of Interstitial Lung Diseases
Outline A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Overview of diagnosis in ILD Why it is important Definition/Classification
More informationA Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco
A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Why it is important Definition/Classification
More informationFollicular bronchiolitis in surgical lung biopsies: Clinical implications in 12 patients
Respiratory Medicine (2008) 102, 307 312 Follicular bronchiolitis in surgical lung biopsies: Clinical implications in 12 patients Michelle R. Aerni a, Robert Vassallo a,, Jeffrey L. Myers b, Rebecca M.
More informationPulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment
Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
More informationDIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY?
NIHR Southampton Respiratory Biomedical Research Unit DIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY? Fibrosing Interstitial Lung Diseases CPFS/WASOG/AIPO/ERS
More informationIPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK?
IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? KEVIN K. BROWN, MD PROFESSOR AND VICE CHAIRMAN, DEPARTMENT OF MEDICINE NATIONAL JEWISH HEALTH DENVER, CO Kevin K.
More informationUsual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease
Eur Respir J 2010; 35: 1322 1328 DOI: 10.1183/09031936.00092309 CopyrightßERS 2010 Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease E.J. Kim*, B.M. Elicker #, F.
More informationDisclosures. Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting. Relevant financial relationships: None. Off-label usage: None
Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona
More informationIdiopathic Interstitial Pneumonias: High-Resolution CT and Histologic Findings1
Idiopathic Interstitial Pneumonias: High-Resolution CT and Histologic Findings1 Nestor L Muller, MD, PhD #{149}Thomas V. Colby, MD Table 1 Classifications of Idiopathic Interstitial Pneumonias Liebow Classification
More informationCombined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases
CASE REPORT Combined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases Nobuhiko Nagata 1, Kentaro Watanabe 2, Michihiro Yoshimi 3, Hiroshi Okabayashi 4, Katsuo Sueishi 5, Kentaro
More informationControversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)
Controversies in Clinical Trials Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF) Controversies to be highlighted by IPF Post-hoc analyses Story Primary end point selection Changing prespecified endpoints
More informationBeyond a consensus classification for idiopathic interstitial pneumonias: progress and controversies
Histopathology 2009, 54, 90 103. DOI: 10.1111/j.1365-2559.2008.03173.x REVIEW Beyond a consensus classification for idiopathic interstitial pneumonias: progress and controversies Jeffrey L Myers & Anna-Luise
More informationDiagnostic challenges in IPF
Medicine, Nursing and Health Sciences Diagnostic challenges in IPF Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University March 2015 Disclosures Consultancy fees from
More informationOverview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy
Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health Disclosures Speaker - Boehringer Ingelheim and Genentech Objectives Describe
More informationJune 2013 Pulmonary Case of the Month: Diagnosis Makes a Difference. Lewis J. Wesselius, MD 1 Henry D. Tazelaar, MD 2
June 2013 Pulmonary Case of the Month: Diagnosis Makes a Difference Lewis J. Wesselius, MD 1 Henry D. Tazelaar, MD 2 Departments of Pulmonary Medicine 1 and Laboratory Medicine and Pathology 2 Mayo Clinic
More informationDisclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:
Disclosures Pharmacological Therapy for ILD What to Use and How to Use It Harold R Collard MD Interstitial Lung Disease Program University of California San Francisco (UCSF) I have relationships with the
More informationARTICLE IN PRESS. Ahuva Grubstein a, Daniele Bendayan b, Ithak Schactman c, Maya Cohen a, David Shitrit b, Mordechai R. Kramer b,
Respiratory Medicine (2005) 99, 948 954 Concomitant upper-lobe bullous emphysema, lower-lobe interstitial fibrosis and pulmonary hypertension in heavy smokers: report of eight cases and review of the literature
More informationHistopathologic Subsets of Fibrosing Alveolitis in Patients with Systemic Sclerosis and Their Relationship to Outcome
Histopathologic Subsets of Fibrosing Alveolitis in Patients with Systemic Sclerosis and Their Relationship to Outcome Demosthenes Bouros, Athol U. Wells, Andrew G. Nicholson, Thomas V. Colby, Vlasis Polychronopoulos,
More informationParenchymal, Interstitial i (Restrictive) i and Vascular Diseases
Pulmonary Diseases: Structure-Function Correlation II Parenchymal, Interstitial i (Restrictive) i and Vascular Diseases Alain C. Borczuk, M.D. Dept of Pathology Pulmonary Diseases: Structure-Function Correlation
More informationT he diagnostic evaluation of a patient with
546 REVIEW SERIES Challenges in pulmonary fibrosis? 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias Michael B Gotway, Michelle M
More informationA 72-year-old male with worsening interstitial infiltrates and respiratory failure
A 72-year-old male with worsening interstitial infiltrates and respiratory failure Case report On November 24, 2004, a 72-year-old male was admitted to the medical intensive care unit (ICU) with a history
More informationRadiologic Approach to Smoking Related Interstitial Lung Disease
Radiologic Approach to Smoking Related Interstitial Lung Disease Poster No.: C-1854 Congress: ECR 2013 Type: Educational Exhibit Authors: K.-N. Lee, J.-Y. Han, E.-J. Kang, J. Kang; Busan/KR Keywords: Toxicity,
More informationProgress in Idiopathic Pulmonary Fibrosis
Progress in Idiopathic Pulmonary Fibrosis David A. Lynch, MB Disclosures Progress in Idiopathic Pulmonary Fibrosis David A Lynch, MB Consultant: t Research support: Perceptive Imaging Boehringer Ingelheim
More informationIdiopathic non-specific interstitial pneumonia: as an autoimmune interstitial pneumonia
Respiratory Medicine (2005) 99, 234 240 Idiopathic non-specific interstitial pneumonia: as an autoimmune interstitial pneumonia Jiro Fujita a,, Yuji Ohtsuki b, Takeo Yoshinouchi c, Ichiro Yamadori d, Shuji
More informationEpidemiology and classification of smoking related interstitial lung diseases
Epidemiology and classification of smoking related interstitial lung diseases Šterclová M. Department of Respiratory Diseases, Thomayer Hospital, Prague, Czech Republic Supported by an IGA Grant No G 1207
More informationSerial computed tomographic evaluation in desquamative interstitial pneumonia
Thorax 1997;52:333 337 333 Serial computed tomographic evaluation in desquamative interstitial pneumonia Masanori Akira, Satoru Yamamoto, Hideki Hara, Mitsunori Sakatani, Einosuke Ueda Abstract a better
More informationCLEARING THE AIR ON DIFFUSE PARENCHYMAL (INTERSTITIAL) LUNG DISEASE (ILD)
CLEARING THE AIR ON DIFFUSE PARENCHYMAL (INTERSTITIAL) LUNG DISEASE (ILD) David Northrop MBA, RRT Assistant Director of Respiratory Therapy Services The University of Kansas Health System Clinical Assistant
More informationChanges in HRCT findings in patients with respiratory bronchiolitis-associated interstitial lung disease after smoking cessation
Eur Respir J 2007; 29: 453 461 DOI: 10.1183/09031936.00015506 CopyrightßERS Journals Ltd 2007 Changes in HRCT findings in patients with respiratory bronchiolitis-associated interstitial lung disease after
More informationThe Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page
The Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page 1135-1140 Role of High Resolution Computed Tomography in Diagnosis of Interstitial Lung Diseases in Patients with Collagen Diseases
More informationRestrictive lung diseases
Restrictive lung diseases Restrictive lung diseases are diseases that affect the interstitium of the lung. Interstitium of the lung is the very thin walls surrounding the alveoli, it s formed of epithelium
More informationClinical significance of respiratory bronchiolitis on open lung biopsy and its relationship to smoking related interstitial lung disease
Thorax 1999;54:1009 1014 1009 James Moon, Ronald M du Bois, Thomas V Colby, David M Hansell, Andrew G Nicholson Interstitial Lung Disease Unit J Moon R M du Bois Department of Radiology D M Hansell Department
More informationBronchoalveolar lavage in fibrotic idiopathic interstitial pneumonias
Respiratory Medicine (2007) 101, 655 660 Bronchoalveolar lavage in fibrotic idiopathic interstitial pneumonias Yon Ju Ryu a, Man Pyo Chung b,, Joungho Han c, Tae Sung Kim d, Kyung Soo Lee d, Eun-Mi Chun
More informationIn medicine, the term overlap is very common, to the extent that there is even a
Case Report Payam Mehrian (MD) 1 Ali Cheraghvandi (MD) 2 Atousa Droudnia (PhD) 3 Firouzeh Talischi (MD) 4 Saeid Fallah Tafti (MD) *5 Shahram Kahkouee (MD) 6 Hamidreza Jamaati (MD) 7 1. Pediatric Respiratory
More informationDiagnosis of Respiratory Bronchiolitis associated interstitial lung disease
Monaldi Arch Chest Dis 2006; 65: 2, 96-101 ORIGINAL ARTICLE Diagnosis of Respiratory Bronchiolitis associated interstitial lung disease C. Robalo Cordeiro 1, S. Freitas 1, B. Rodrigues 1, A. Catarino 1,
More informationIdiopathic pulmonary fibrosis (IPF), also referred to as
Operation for Lung Cancer in Patients With Idiopathic Pulmonary Fibrosis: Surgical Contraindication? Toshio Fujimoto, MD, Tsuyoshi Okazaki, MD, Tadashi Matsukura, MD, Takeshi Hanawa, MD, Naoki Yamashita,
More informationUsual Interstitial Pneumonia and Non-Specific Interstitial Pneumonia: Serial Thin-Section CT Findings Correlated with Pulmonary Function
Usual Interstitial Pneumonia and Non-Specific Interstitial Pneumonia: Serial Thin-Section CT Findings Correlated with Pulmonary Function Yeon Joo Jeong, MD 1, 2 Kyung Soo Lee, MD 1 Nestor L. Muller, MD
More informationTreatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone Results of a Prospective, Open-label Phase II Study
Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone Results of a Prospective, Open-label Phase II Study GANESH RAGHU, W. CRAIG JOHNSON, DIANE LOCKHART, and YOLANDA MAGETO
More informationLimitations of Corticosteroids and Cytotoxic Agents in Treating Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis Limitations of Corticosteroids and Cytotoxic Agents in Treating Idiopathic Pulmonary Fibrosis JMAJ 46(11): 475 482, 2003 Kingo CHIDA Associate Professor, Second Division,
More informationManish Powari Regional Training Day 10/12/2014
Manish Powari Regional Training Day 10/12/2014 Large number of different types of Interstitial Lung Disease (ILD). Most are very rare Most patients present with one of a smaller number of commoner diseases
More informationCOI: no conflicts of interest to declare
Idiopathic versus secondary Usual Interstitial Pneumonia (UIP) pattern in a series of 96 consecutive surgical lung biopsies: The value of histologic ancillary findings in a multidisciplinary discussion
More informationThree Cases of Non-specific Interstitial Pneumonia Associated with Primary Lung Cancer
CASE REPORT Three Cases of Non-specific Interstitial Pneumonia Associated with Primary Lung Cancer Toshio SATO, Ichiro YAMADORI, Jiro FUJITA*, Noboru HAMADA, Toshiro YONEI, Shuji BANDOH*, Yuji OHTSUKI**
More informationPathologic Assessment of Interstitial Lung Disease
Pathologic Assessment of Interstitial Lung Disease Dry and itchy? It could be eczema or fungal infection. We don t need to worry, the drugs aren t that dangerous. Kirk D. Jones, MD UCSF Dept. of Pathology
More informationI n 2002 the American Thoracic Society (ATS) and
1008 REVIEW SERIES Challenges in pulmonary fibrosis? 5: The NSIP/UIP debate Roland du Bois, Talmadge E King Jr... Among the idiopathic interstitial s, the two entities idiopathic pulmonary fibrosis (IPF)
More informationTBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than
TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than PAP) BAL is not required as a diagnostic tool in patients
More informationIdiopathic interstitial pneumonias (IIPs) are a group of
SYMPOSIA C. Isabela S. Silva, MD, PhD and Nestor L. Müller, MD, PhD Abstract: The idiopathic interstitial pneumonias (IIPs) are a group of diffuse parenchymal lung diseases of unknown etiology characterized
More informationChallenges in the Diagnosis of Interstitial Lung Disease
Challenges in the Diagnosis of Interstitial Lung Disease Kirk D. Jones, MD UCSF Dept. of Pathology kirk.jones@ucsf.edu Overview New Classification of IIP Prior classification Modifications for new classification
More informationCriteria for confident HRCT diagnosis of usual interstitial pneumonia (UIP)
Criteria for confident HRCT diagnosis of usual interstitial pneumonia (UIP) Assem El Essawy (1) & Amr A. Nassef (٢) Abstract Identification of interstitial pneumonia (IP) was mainly based on histological
More informationPatient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens
Patient with FVC>90% predicted Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 63-year-old, male patient with progressive exertional dyspnoea lasting for 2 years and dry cough
More informationChallenges in the Diagnosis of Interstitial Lung Disease
Challenges in the Diagnosis of Interstitial Lung Disease Kirk D. Jones, MD UCSF Dept. of Pathology kirk.jones@ucsf.edu Overview New Classification of IIP Prior classification Modifications for new classification
More informationClassifying interstitial lung diseases in a fractal lung: a morphologist9s view "anno Domini 2000"
Eur Respir J 2001; 18: Suppl. 32, 107s 113s Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0904-1850 ISBN 1-904097-01-4 SELECTED REPORT Classifying
More informationIdiopathic pulmonary fibrosis (IPF) is the. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis
Eur Respir J 2010; 36: 1067 1072 DOI: 10.1183/09031936.00152609 CopyrightßERS 2010 A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis O. Nishiyama*,", H. Taniguchi*,
More informationRadiological features of idiopathic interstitial pneumonia: a pictorial review
Radiological features of idiopathic interstitial pneumonia: a pictorial review Poster No.: C-2012 Congress: ECR 2013 Type: Educational Exhibit Authors: M. Piccoli, F. Roccasalva, S. Palmucci, G. Cappello,
More informationINTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF)
INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF) Marilyn K. Glassberg Csete, M.D. Professor of Medicine, Surgery, and Pediatrics Director, Interstitial and Rare Lung Disease Program
More informationBronkhorst colloquium Interstitiële longziekten. Katrien Grünberg, klinisch patholoog
Bronkhorst colloquium 2013-2014 Interstitiële longziekten De pathologie achter de CT Katrien Grünberg, klinisch patholoog K.grunberg@vumc.nl Preparing: introduction and 3 cases The introduction on microscopic
More informationThe concept of respiratory bronchiolitis/interstitial lung
Respiratory Bronchiolitis/Interstitial Lung Disease Fibrosis, Pulmonary Function, and Evolving Concepts Andrew Churg, MD; Nestor L. Müller, MD, PhD; Joanne L. Wright, MD Context. The concept of respiratory
More informationHypersensitivity Pneumonitis: Epidemiology and Classification
Hypersensitivity Pneumonitis: Epidemiology and Classification Ulrich Costabel, MD University of Duisburg-Essen, Ruhrlandklinik Department of Pneumology/Allergy Objectives Definitions, Etiology Epidemiology
More informationUpdate on Therapies for Idiopathic Pulmonary Fibrosis. Outline
Update on Therapies for Idiopathic Pulmonary Fibrosis Paul Wolters Associate Professor University of California, San Francisco Outline Classification of Interstitial lung disease Clinical classification
More informationCryptogenic Organizing Pneumonia: Serial High-Resolution CT Findings in 22 Patients
Cardiopulmonary Imaging Original Research Lee et al. High-Resolution CT of Cryptogenic Organizing Pneumonia Cardiopulmonary Imaging Original Research Ju Won Lee 1 Kyung Soo Lee 1 Ho Yun Lee 1 Man Pyo Chung
More informationDefinition, classification and epidemiology
Interstitial Lung Diseases Definition, classification and epidemiology Haluk Türktaş Professor of Pulmonary Medicine Gazi University Ankara Interstitial Lung Diseases Definition of ILD A diverse group
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationUNRAVELING THE ETIOLOGY OF FAMILIAL INTERSTITIAL PNEUMONIA: GENETIC INVESTIGATIONS OF A COMPLEX DISEASE. Anastasia Leigh Wise
UNRAVELING THE ETIOLOGY OF FAMILIAL INTERSTITIAL PNEUMONIA: GENETIC INVESTIGATIONS OF A COMPLEX DISEASE by Anastasia Leigh Wise University Program in Genetics and Genomics & Integrated Toxicology and Environmental
More informationImaging: how to recognise idiopathic pulmonary fibrosis
REVIEW IDIOPATHIC PULMONARY FIBROSIS Imaging: how to recognise idiopathic pulmonary fibrosis Anand Devaraj Affiliations: Dept of Radiology, St George s Hospital, London, UK. Correspondence: Anand Devaraj,
More informationPulmonary fibrosis: rate of disease progression as a trigger for referral for lung transplantation
LUNG TRANSPLANTATION Pulmonary fibrosis: rate of disease progression as a trigger for referral for lung transplantation Laura S Mackay, Rachel L Anderson, Gareth Parry, James Lordan, Paul A Corris, Andrew
More informationH ypersensitivity pneumonitis (HP) comprises a group of
665 INTERSTITIAL LUNG DISEASE Chronic bird fancier s lung: histopathological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias
More information